Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2010

View Archived Issues

TEAMSTA trial data support efficacy of telmisartan/amlodipine combination

Sanwa describes preclinical pharmacology of SKL-18287 and SKL-19014

Clinical trials show potential of ASP-1941 to treat type 2 diabetes

Ardea describes next-generation URAT-1 inhibitor RDEA-684

Phase I data presented on SBI-087 in RA and SLE

Deuterated edaravone derivatives synthesized at Auspex

PolyMedix receives NIH grant to develop antimalarial agents

BioBlocks describes new anticancer compounds

Platco reports platinum complexes with antiproliferative activity

Merck & Co. describes new gamma-secretase modulators for AD

Crucell and Sanofi Pasteur restructure partnership in pediatric and respiratory vaccines

Cempra pays Optimer milestone for oral macrolide CEM-101

FDA warns of risk of serious hematological reactions with off-label Qualaquin use

Curis to receive milestone from Debiopharm for Debio-0932

EMA commences review of rosiglitazone-containing medicines

Fibrocell reports full enrollment in histology trial of azficel-T

Tamir Biotechnology selects CRO for phase II ranpirnase trial

Proximagen and NIH collaborate on phase II naluzotan trial

Eurocine Vaccines reports phase I/II data of its nasal influenza vaccine

Sanofi-aventis claims new casein kinase I inhibitors

Merck Serono's cladribine tablets approved for RRMS in Russia

Botox licensed in U.K. for prophylaxis of chronic migraine

Global registrational trial announced for rFVIIIFc in hemophilia A

FDA grants priority review to Sprycel sNDA in newly diagnosed CML

Genentech and MRC partner on small molecules for neurological disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...